Platinum Investment Management Ltd. Grows Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Platinum Investment Management Ltd. lifted its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 82.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,533 shares of the company's stock after purchasing an additional 34,659 shares during the period. Platinum Investment Management Ltd. owned about 0.10% of Kura Oncology worth $667,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in KURA. Point72 DIFC Ltd bought a new stake in Kura Oncology in the third quarter worth about $146,000. E Fund Management Co. Ltd. bought a new stake in shares of Kura Oncology in the 4th quarter worth approximately $90,000. Erste Asset Management GmbH purchased a new position in Kura Oncology in the third quarter valued at approximately $215,000. Corient Private Wealth LLC purchased a new position in Kura Oncology in the fourth quarter valued at approximately $109,000. Finally, Bellevue Group AG grew its holdings in Kura Oncology by 36.0% during the third quarter. Bellevue Group AG now owns 13,600 shares of the company's stock valued at $266,000 after purchasing an additional 3,600 shares during the period.

Insider Activity

In related news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares in the company, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Thomas James Doyle sold 4,949 shares of the business's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,729 shares of company stock valued at $92,307. Insiders own 5.50% of the company's stock.

Remove Ads

Kura Oncology Price Performance

Shares of Kura Oncology stock traded down $0.01 during trading on Friday, hitting $7.84. The stock had a trading volume of 2,172,610 shares, compared to its average volume of 1,061,122. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 12 month low of $6.79 and a 12 month high of $23.48. The firm has a market cap of $633.12 million, a price-to-earnings ratio of -3.32 and a beta of 0.85. The business's 50-day moving average is $7.82 and its 200 day moving average is $12.43.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analysts' expectations of $57.96 million. As a group, sell-side analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Wall Street Analyst Weigh In

KURA has been the topic of a number of recent research reports. JMP Securities reiterated a "market outperform" rating and set a $28.00 price target on shares of Kura Oncology in a research note on Thursday, February 6th. StockNews.com lowered shares of Kura Oncology from a "buy" rating to a "hold" rating in a research report on Tuesday, March 18th. Wedbush reissued an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. BTIG Research cut shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. Finally, Cantor Fitzgerald upgraded shares of Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $25.50.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.